cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Vertex Pharmaceuticals Incorporated
88 own
59 watching
Current Price
$396.55
$-3.68
(-0.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
112,834.59M
52-Week High
52-Week High
448.39999
52-Week Low
52-Week Low
316.42999
Average Volume
Average Volume
1.2M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
23.0149
iconMarket Capitalization112,834.59M
icon52-Week High448.39999
icon52-Week Low316.42999
iconAverage Volume1.2M
iconDividend Yield--
iconP/E Ratio23.0149
What does the Vertex Pharmaceuticals Incorporated do?
Vertex Pharmaceuticals Incorporated discovers, develops, manufactures, and commercializes medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene. The company also develops Tezacaftor (VX-661), a corrector compound that is in a Phase III development program in combination with ivacaftor in multiple CF patients; VX-152 and VX-440 that are CFTR corrector compounds in Phase II clinical trials, as well as VX-659 and VX-445 that are CFTR corrector compounds in Phase I clinical trials; and VX-371, an investigational epithelial sodium channel, which is in a Phase II development program. In addition, it engages in the research and mid-and early-stage development programs in the areas of oncology, pain, and neurology. The company sells its products primarily to specialty pharmacy providers and wholesalers in North America, as well as government-owned and supported customers internationally. Vertex Pharmaceuticals Incorporated has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; Parion Sciences, Inc.; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Merck KGaA; and Janssen Pharmaceuticals, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Read More
How much money does Vertex Pharmaceuticals Incorporated make?
News & Events about Vertex Pharmaceuticals Incorporated.
InvestorPlace
9 months ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In researching this article, we used AI to help make predictions for potential triple-digit return biotech stocks by 2025 The post 3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025 appeared first on ...
Business Wire
9 months ago
Vertex Pharmaceuticals today announced that the European Commission has granted approval for the label extension of ORKAMBI (lumacaftor/ivacaftor) for the treatment of children with cystic fibrosis (CF) ages 1 to <2 years old who have two copies of the F508del mutation in the cystic fibrosis...
Business Wire
9 months ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2023 financial results on Tuesday, August 1, 2023 after the financial markets close. The company will host a...
Ticker Report
10 months ago
Vertex Pharmaceuticals (NASDAQ:VRTX Get Rating) had its price target hoisted by Royal Bank of Canada from $315.00 to $323.00 in a research report sent to investors on Thursday, The Fly reports. Other analysts have also issued reports about the stock. SVB Securities lowered their price ...
Business Wire
10 months ago
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that both pivotal trials for exagamglogene autotemcel (exa-cel) in patients with transfusion-dependent beta thalassemia (TDT) or severe sickle cell disease (SCD) met primary and key secondary...
Frequently Asked Questions
Frequently Asked Questions
What is Vertex Pharmaceuticals Incorporated share price today?
plus_minus_icon
Can Indians buy Vertex Pharmaceuticals Incorporated shares?
plus_minus_icon
How can I buy Vertex Pharmaceuticals Incorporated shares from India?
plus_minus_icon
Can Fractional shares of Vertex Pharmaceuticals Incorporated be purchased?
plus_minus_icon
What are the documents required to start investing in Vertex Pharmaceuticals Incorporated stocks?
plus_minus_icon
What is today’s traded volume of Vertex Pharmaceuticals Incorporated?
plus_minus_icon
What is today’s market capitalisation of Vertex Pharmaceuticals Incorporated?
plus_minus_icon
What is the 52-Week High and Low Range of Vertex Pharmaceuticals Incorporated?
plus_minus_icon
What percentage is Vertex Pharmaceuticals Incorporated down from its 52-Week High?
plus_minus_icon
What percentage is Vertex Pharmaceuticals Incorporated up from its 52-Week Low?
plus_minus_icon
Current Price
$396.55
$-3.68
(-0.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00